In conclusion, these data have identified mutant APC as a tumor biomarker that may predict poor responders to the common 5-FU treatment and we propose that the inhibition of Chk1 targeting selectively APC-mutant populations in colon cancer cells may provide a more effective strategy for chemosensitization to 5-FU. The gene discussed is APC; the disease is colonic neoplasm.